ArticleHarm reduction journal2009
Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis.
Article in Harm reduction journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- The effects of exercise with nicotine replacement therapy for smoking cessation in adults: A systematic review.Frontiers in psychiatry · 2022Pooled it
- Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis.BMC clinical pharmacology · 2011Pooled it
- Natural Products-Pyrazine Hybrids: A Review of Developments in Medicinal Chemistry.Molecules (Basel, Switzerland) · 2023Review
- Article
- The impact of covariance priors on arm-based Bayesian network meta-analyses with binary outcomes.Statistics in medicine · 2020Article
- Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review.Frontiers in psychiatry · 2019Review
- Discovery and development of varenicline for smoking cessation.Expert opinion on drug discovery · 2018Review
- Medications for alcohol use disorders: An overview.Pharmacology & therapeutics · 2018Review
- Sensitivity to Excluding Treatments in Network Meta-analysis.Epidemiology (Cambridge, Mass.) · 2016Article
- Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.Progress in neuro-psychopharmacology & biological psychiatry · 2016Review
- Article
- Secondary prevention after ischaemic stroke: the ASPIRE-S study.BMC neurology · 2015Article
- Nicotinic receptor antagonists as treatments for nicotine abuse.Advances in pharmacology (San Diego, Calif.) · 2014Review
- Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study.BMJ (Clinical research ed.) · 2013Article
- Evaluation of inconsistency in networks of interventions.International journal of epidemiology · 2013Article
- Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection.Clinical epidemiology · 2013Article
- Smoking and HIV: prevalence, health risks, and cessation strategies.Current HIV/AIDS reports · 2012Review
- Smoking cessation intervention in a cardiovascular hospital based clinical setting.Cardiovascular psychiatry and neurology · 2012Article
- Multiple treatment comparison meta-analyses: a step forward into complexity.Clinical epidemiology · 2011Article
- Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial.American journal of public health · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmoking cessation has important immediate health benefits. The comparative short-term effectiveness of smoking cessation interventions is not well known. We aimed to determine the relative effectiveness of nicotine replacement therapy (NRT), bupropion and varenicline at 4 weeks post-target quit date.
methodsWe searched 10 electronic medical databases (inception to October 2008). We selected randomized clinical trials [RCTs] evaluating interventions for our primary outcome of abstinence from smoking at at-least 4 weeks post-target quit date, with biochemical confirmation. We conducted random-effects odds ratio (OR) meta-analysis and meta-regression. We compared treatment effects across interventions using head-to-head trials and calculated indirect comparisons.
resultsWe combined a total of 101 trials evaluating delivery of NRT versus inert controls at approximately 4 weeks post-target quit date (total n = 31,321). The pooled overall OR is OR 2.05 (95% Confidence Interval [CI], 1.89-2.23, P =< 0.0001). We pooled data from 31 bupropion trials contributing a total n of 11,118 participants and found a pooled OR of 2.25 (95% CI, 1.94-2.62, P =< 0.0001). We evaluated 9 varenicline trials compared to placebo. Our pooled estimate for cessation at 4 weeks post-target quit date found a pooled OR of 3.16 (95% CI, 2.55-3.91, P =< 0.0001). Two trials evaluated head to head comparisons of varenicline and bupropion and found a pooled estimate of OR 1.86 (95% CI, 1.49-2.33, P =< 0.0001 at 4 weeks post-target quit date. Indirect comparisons were: NRT and bupropion, OR, 1.09, 95% CI, 0.93-1.31, P = 0.28; varenicline and NRT, OR 1.56, 95% CI, 1.23-1.96, P = 0.0002; and, varenicline and bupropion, OR 1.40, 95% CI, 1.08-1.85, P = 0.01.
conclusionPharmacotherapeutic interventions are effective for increasing smoking abstinence rates in the short-term.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.